© Copyright Our Wall
The “Global Cell
Cytometry Market: Focus on High Throughput Flow Cytometers and Image
Cytometers, 2022-2035” report features an extensive study on the current market
landscape, offering an informed opinion on the likely adoption of the global
cell cytometry in the healthcare industry, in the mid to long term.
Key Inclusions
§
A general overview of cell cytometry,
featuring information on the different types of cytometry, namely high
throughput flow
cytometryand image
cytometry, along with details on their advantages
and limitations. Further, the chapter presents an array of Google trends
analysis, highlighting the emerging focus areas, key historical trends, and
geographical activity, offering insights on how this field has evolved over the
last five years.
§
A detailed assessment of the market
landscape of high throughput flow
cytometersbased on several relevant parameters,
such as type of high throughput flow cytometer, throughput rate (wells per
minute), detection rate, type of plate format, number of color channels, number
of laser channels, number of detection channels, sample volume (in µl), type of
detection mechanism(s), and application(s). In addition, the chapter includes
analysis of high throughput flow cytometer developers, along with information
on their year of establishment, company size, location of headquarters and
leading players (in terms of number of products offered).
§
An insightful product competitiveness
analysis of high throughput flow cytometers, based on developer power (based on
the experience of the developer in this industry), and product competitiveness
(in terms of type of high throughput flow cytometer, throughput rate, detection
rate, type of plate format, number of color channels, number of laser channels,
number of detection channels, product dimensions, sample volume (in µl), type
of detection mechanism(s) and application(s)).
§
A detailed assessment of the market
landscape ofimage cytometers based on several relevant parameters, such
as type of image cytometer, processing time, type of plate format, output
format, sample volume, and application(s). In addition, the chapter includes
analysis of image cytometer developers, along with information on their year of
establishment, company size, location of headquarters and leading players (in
terms of number of products being offered).
§
An insightful product competitiveness
analysis of image cytometers, based on developer power (based on the experience
of the developer in this industry), and product competitiveness (in terms of
type of image cytometer, processing time, output format, average sample volume
and application(s)).
§
Elaborate profiles of prominent players
(shortlisted based on a proprietary criterion) engaged in the development /
commercialization of cell cytometers (high throughput flow cytometers and image
cytometers). Each profile features a brief overview of the company, recent
developments and an informed future outlook.
§
An insightful analysis of the
partnerships that have been inked within the global cell cytometry industry
since 2017, based on several relevant parameters, such as year of partnership,
type of partnership (acquisitions, asset acquisitions, commercialization
agreements, commercialization and distribution agreements, distribution
agreements, product development
agreements storage and distribution agreements and others), most active players
(in terms of number of deals inked) and regional distribution of partnership
activity.
§
An analysis of various recent
developments / trends related to global cell cytometry domain, offering
insights on the funding activity in this domain, based on several relevant
parameters, such as year of funding, type of funding, amount invested (USD
Million), most active players (in terms of number of instances and amount
raised), and most active investors (in terms of number of instances). In
addition, it provides information on the analysis of the global events attended
by the participants, based on several relevant parameters, such as year of
event, event platform, type of event, most active organizers (in terms of
number of events) and most active organizations (in terms of number of
participants).
§
An insightful analysis of the patents
filed / granted for cell cytometry, since 2020, taking into consideration
various relevant parameters, such as type of patent, publication year, annual
number of granted patents and patent applications, geographical location, CPC
symbols, emerging focus areas, type of organization, leading players (in terms
of number of patents granted / filed) and patent characteristics. In addition,
the chapter includes a detailed patent benchmarking and an insightful valuation
analysis.
A
detailed market forecast, featuring analysis of the current and projected
future opportunity across key market segments (listed below):
§ Type of Cytometer
§
High
Throughput Flow Cytometer
§
Image
Cytometer
§ Company Size
§ Very Small
§ Small
§ Mid-sized
§ Large
§ Very Large
§ Key Geographical Regions
§ North America
§ Europe
§ Asia-Pacific
§ Rest of the World
Key
Questions Answered
§
Who are the leading players engaged in
the development of high throughput flow cytometers and image cytometers?
§
Which are the popular types of cytometers
available in the market?
§
Which partnership models are commonly
adopted by stakeholders engaged in this industry?
§
What are the investment trends and who
are the key investors actively engaged in the development and commercialization
of cell cytometers?
§
What are the key agenda items being
discussed in various global events / conferences held related to cell cytometry
platforms?
§
How is the current and future market
opportunity likely to be distributed across key market segments?
To
view more details on this report, click on the link:
https://www.rootsanalysis.com/reports/cell-cytometry-market.html
Learn
from experts: do you know about these
emerging industry trends?
Modular
Construction – Retrofitting Conventional Buildings
Digital Therapies: The
“Digital Pills” of current generation
About Roots Analysis
Roots Analysis is a global leader in the
pharma / biotech market research. Having worked with over 750 clients
worldwide, including Fortune 500 companies, start-ups, academia, venture
capitalists and strategic investors for more than a decade, we offer a highly
analytical / data-driven perspective to a network of over 450,000 senior
industry stakeholders looking for credible market insights.
Learn more about Roots
Analysis consulting services:
Roots Analysis Consulting - the
preferred research partner for global firms
Contact:
Ben Johnson
+1 (415) 800 3415
Roots Analysishas done a detailed study
on Cell Free System: Cell Free Expression Kits and Service Providers,
2023-2035, covering key aspects of the industry’s evolution and identifying
potential future growth opportunities.
Key Market Insights
§
Presently,
more than 35 players across the globe claim to offer cell free expression
services for synthesis of a variety of biomolecules
§
The
current market landscape is fragmented, featuring the presence of both new
entrants and established players catering to needs of various industries;
majority of these players are based in the US
§
In
pursuit of building a competitive edge in this field, stakeholders are actively
upgrading their existing capabilities and adding new competencies in order to
enhance their respective service portfolios
§
More
than 90 cell free expression kits are currently available in the market for the
synthesis of different types of biomolecules; these kits utilize different
types of host organisms for cell free expression
§
Cell
free expression kits utilize a range of cell
free expression systemfor
the synthesis of different types of biologics; majority of these include
proteins, followed by oligonucleotides and others
§
Owing
to the rise in demand for difficult to express biomolecules, the requirement of
cell free expression is increasing, prompting the stakeholders to upgrade their
product offerings
§
Since
2015, more than 430 patents have been filed / granted by various stakeholders
in order to protect the intellectual property generated within this field
§
The
growing interest is evident from the rise in partnership activity; in fact, the
maximum number of collaborations related to cell
free systemswere inked
in 2022
§
Several
investors having realized the opportunity within this domain, have invested
more than USD 8 billion across various funding rounds in the past six years
§
The
cell free expression market is likely to grow at a CAGR of 7.1%, till 2035;
this opportunity is expected to be well distributed across different types of
cell free systems, host organisms and expression methods
§
Growth
in this domain is anticipated to be primarily driven by the rising demand for
biologics; North America is expected to capture larger share (over 50%) of the
market by 2035
Table of Contents
1. PREFACE
1.1. Cell
Free System Overview
1.2. Key
Market Insights
1.3. Scope
of the Report
1.4.
Research Methodology
1.5.
Frequently Asked Questions
1.6.
Chapter Outlines
2.
EXECUTIVE SUMMARY
3.
INTRODUCTION
3.1.
Chapter Overview
3.2. Introduction
to Cell Free Systems
3.3.
Overview of Cell Free Biomanufacturing
3.4.
Applications of Cell Free Biomanufacturing
3.5.
Future Perspectives
4. MARKET
LANDSCAPE: CELL FREE EXPRESSION SERVICE PROVIDERS
4.1.
Chapter Overview
4.2. Cell
Free Expression Service Providers: Overall Market Landscape
5. MARKET
LANDSCAPE: CELL FREE EXPRESSION KITS
5.1.
Chapter Overview
5.2. Cell
Free Expression Kits: Overall Market Landscape
5.3. Cell
Free Expression Kit Providers Landscape
6. CELL
FREE EXPRESSION SERVICE PROVIDERS: COMPANY COMPETITIVENESS ANALYSIS
6.1.
Chapter Overview
6.2.
Assumptions and Key Parameters
6.3.
Methodology
6.4.
Company Competitiveness Analysis: Cell Free Expression Service Providers
7. CELL
FREE EXPRESSION KITS: PRODUCT COMPETITIVENESS ANALYSIS
7.1.
Chapter Overview
7.2.
Assumptions and Key Parameters
7.3.
Methodology
7.4.
Product Competitiveness Analysis: Cell Free Expression Kits
8. COMPANY
PROFILES: CELL FREE EXPRESSION SERVICE PROVIDERS
8.1.
Chapter Overview
8.2. BioLinker
8.2.1.
Company Overview
8.2.2.
Cell Free Expression Service Portfolio
8.2.3.
Recent Developments and Future Outlook
8.3.
CUSABIO
8.4.
LenioBio
8.5.
Touchlight
9. COMPANY
PROFILES: CELL FREE EXPRESSION KIT PROVIDERS
9.1.
Chapter Overview
9.2.
biotechrabbit
9.3.
CellFree Sciences
9.4.
Creative Biolabs
9.5.
Diacel Arbor Biosciences
9.6.
Promega
9.7.
Thermo Fisher Scientific
10.
PARTNERSHIPS AND COLLABORATIONS
10.1.
Chapter Overview
10.2.
Partnership Models
10.3. Cell
free System: Partnerships and Collaborations
11.
FUNDING AND INVESTMENT ANALYSIS
11.1.
Chapter Overview
11.2.
Types of Funding
11.3. Cell
free System: Funding and Investment Analysis
12. PATENT
ANALYSIS
12.1.
Chapter Overview
12.2.
Scope and Methodology
12.3. Cell
free System: Patent Analysis
12.4. Cell
free System: Patent Benchmarking Analysis
12.5. Cell
free System: Patent Valuation
12.6.
Leading Patents: Analysis by Number of Citations
13. MARKET
FORECAST AND OPPORTUNITY ANALYSIS
13.1.
Chapter Overview
13.2. Key
Assumptions and Forecast Methodology
13.3.
Global Cell Free Market, 2023-2035
14.
EXECUTIVE INSIGHTS
14.1.
Chapter Overview
14.2. Gene
Frontier
14.3.
LenioBio
14.4.
Synthelis
15.CONCLUDING
REMARKS
16.
APPENDIX 1: TABULATED DATA
17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
For
additional details, please visit https://www.rootsanalysis.com/reports/cell-free-expression-market.html
Learn from
experts: do you know about these
emerging industry trends?
Modular
Construction – Retrofitting Conventional Buildings
Long-Acting Drug
Delivery: A Novel Pharmacological Strategy to Deliver Therapeutic Modalities
About Roots Analysis
Roots Analysis is a global leader in the
pharma / biotech market research. Having worked with over 750 clients
worldwide, including Fortune 500 companies, start-ups, academia, venture
capitalists and strategic investors for more than a decade, we offer a highly
analytical / data-driven perspective to a network of over 450,000 senior
industry stakeholders looking for credible market insights.
Learn more about Roots
Analysis consulting services:
Roots Analysis Consulting - the
preferred research partner for global firms
Contact:
Ben Johnson
+1 (415) 800 3415
The “Non-Viral
Transfection Reagents and Systems Market (2nd Edition), 2023-2035”
report features an extensive study of the current landscape and likely future
potential of companies developing non-viral transfection reagents and systems
Key
Inclusions
§ An executive summary of the insights captured during
our research. It offers a high-level view on the current state of non-viral
transfection reagents and systems market and its likely evolution in the mid-long term.
§
A general
overview of non-viral
transfection reagentsand systems,
highlighting details on transfection
methods and its applications, such as advanced therapy medicinal product
development, gene silencing, bioproduction of therapeutic protein and stem cell
engineering. It also provides information on the different methods of
transfection (viral and non-viral), types of viral vectors (AAV, adenoviral,
lentiviral, retroviral and others), along with details on chemical methods
(lipoplexes, polyplexes, lipoplexes and others) and physical methods
(electroporation, gene gun, sonoporation, magnetofection and others) of
transfection.
§ A
detailed assessment of the overall market landscape of the companies developing
non-viral transfectionreagents, based on several relevant parameters, such as type of carrier used
(lipid-based carrier, polymer-based carrier, protein-based carrier,
nanotechnology-based carrier, calcium phosphate-based carrier and
minicircle-based carrier), compatible cell type (human cell, monkey cell,
murine cell and other cell), type of molecule delivered (DNA and RNA), and
serum compatibility (serum free and serum compatibility). It also features
information on the non-viral transfection reagent suppliers, highlighting the
year of establishment, company size and location of headquarters.
§ A
detailed assessment of the overall market landscape of the companies developing
electroporation-based non-viral transfection systems. The relevant parameters
used for the assessment include, compatible cell type (human mammalian cells
and other mammalian cells) and type of molecule delivered (DNA and RNA). It
also features information on the electroporation transfection systems
suppliers, highlighting the year of establishment, company size and location of
headquarters.
§ A
detailed assessment of the overall market landscape of the companies developing
other non-viral transfection systems. The relevant parameters used for the
assessment include, compatible cell type (human mammalian cells and other
mammalian cells) and type of molecule delivered (DNA and RNA). It also features
information on the other non-viral transfection systems suppliers, highlighting
the year of establishment, company size and location of headquarters.
§ An
in-depth company competitiveness analysis of non-viral transfection reagent and
system suppliers based in North America, Europe and Asia-Pacific.The analysis compares various
suppliers based on supplier strength (in terms of years of experience and
company size) and product portfolio strength (type of carrier used, compatible
cell type, type of molecule delivered and serum compatibility).
§ A detailed technology competitiveness analysis of
electroporation transfection systems and other non-viral transfection systems,
taking into consideration the supplier
strength(based on the year of
establishment and company size of developer) and product portfolio strength (in
terms of compatible cell typeand type of molecule delivered).
§ Tabulated
profiles of key players engaged in the development of non-viral transfection reagentsand systems (shortlisted based on the type of carrier used, compatible cell
type, type of molecule delivered and serum
compatibility). Each profile includes a brief overview of the company,
financial information (if available), recent developments and an informed
future outlook.
§ An
in-depth analysis of over 80 cell (including TCR and CAR-T cell) and gene
therapy developers that are likely to partner with non-viral transfection
reagent and system suppliers, based on several relevant parameters, such as
pipeline maturity (which takes into account the phase of development), supplier
strength (in terms of number of employees), pipeline strength (based on the
number of non-viral transfection reagents in pipeline), and type of therapy.
§ A
detailed analysis of more than 450 peer-reviewed, scientific articles focused
on non-viral transfection reagents and systems that have been published since
2015, based on year of publication, type of publication, type of molecule
delivered, target therapeutic area, key focus areas, popular cells and cell
lines. The chapter also highlights the leading publishers across different
geographies, key journals (in terms of number of articles published).
§
An insightful framework to understand the pricing
strategy of the non-viral transfection reagents offered by a company, along
with its competitive position in the market. In addition, it presents the
equation devised to calculate the likely price of non-viral transfection
reagents based upon their characteristics.
§ Non-Viral Based Transfection Methods
§ Chemical-based Methods
§ Physical-based Methods
§ Other Methods
§ End-Users
§ Academic And Research Institutions
§ Stem Pharmaceutical Companies
§ Other End-Users
§ Area Of Application
§ Clinical Applications
§ Research Applications
§ Key Geographical Regions
§ North America
§ Europe
§ Asia-Pacific
§ Rest of the World (RoW)
Key Questions Answered
§ How is the research and development
(R&D) activity evolving in the non-viral transfection reagents and systems
market?
§ How many companies offer non-viral
transfection reagents and systems?
§ What are the different types of
initiatives being undertaken by big pharma players for the manufacturing of
non-viral transfection reagents and systems?
§ Which segment is likely to capture the
largest share in the non-viral transfection reagents and systems market?
§ How is the non-viral transfection reagents
and systems market likely to evolve in the coming years?
To
view more details on this report, click on the link:
https://www.rootsanalysis.com/reports/view_document/non-viral-transfection/307.html
Learn from
experts: do you know about these
emerging industry trends?
Medical Device
Coatings and Modification Technologies
The Future of
Dentistry: Dental 3D Printing
Learn from our recently published
whitepaper: -
Next
Generation Biomanufacturing – The Upcoming Era of Digital Transformation
About Roots Analysis
Roots Analysis is a global leader in the
pharma / biotech market research. Having worked with over 750 clients
worldwide, including Fortune 500 companies, start-ups, academia, venture
capitalists and strategic investors for more than a decade, we offer a highly
analytical / data-driven perspective to a network of over 450,000 senior
industry stakeholders looking for credible market insights.
Learn more about Roots
Analysis consulting services:
Roots Analysis Consulting - the
preferred research partner for global firms
Contact:
Ben Johnson
+1 (415) 800 3415
The
DNA encoded library market is currently abuzz with activity; industry players
have forged several strategic alliances and received significant financial
support from investors. This can be attributed to the various benefits offered
by these platforms, such as cost effectiveness, high diversity, minimal false
positives, stability and rapid hit identification.
The financial opportunity within the DNA encoded library markethas been analyzed across the following
segments:
§ Application Area
§ Other Application Areas
§ Therapeutic Area
§ Oncological Disorders
§ Immunological Disorders
§ Neurological Disorders
§ Respiratory Disorders
§ Dermatological Disorders
§ Cardiovascular Disorders
§ Infectious Diseases
§ Other Therapeutic Areas
§ End-user
§ Other End-users
§ Type of Payment Model Employed
§ Key Geographical Regions
§ North America
§ Europe
§ Asia-Pacific
The
research also includes detailed profiles of key players (listed below) offering
DNA encoded libraryplatforms and services; each profile features a brief overview of the company,
its financial information (if available), details on platform and service
portfolio, recent developments and an informed future outlook.
§ AlphaMa
§ DICE
Therapeutics
§ DyNAbind
§ HitGen
§ NovAliX
§ Vipergen
§ WuXi
AppTec
§ X-Chem
Table of Contents
1. Preface
2. Executive Summary
3. Introduction
4. Market
Landscape
5. Business
Model Analysis
6. Company
Competitiveness Analysis
7. Company
Profiles
8.
Partnerships and Collaborations
9. Global
Event Analysis
10. Patent
Analysis
11. Big
Pharma Initiatives
12. Case
Study: Companies / Organizations Supporting the Development of DNA Encoded
Libraries
13. Market
Forecast and Opportunity Analysis
14.
Concluding Remarks
15.
Executive Insights
16.
Appendix 1: Tabulated Data
17.
Appendix 2: List of Companies and Organizations
To
view more details on this report, click on the link:
https://www.rootsanalysis.com/reports/view_document/dna-encoded-libraries/288.html
Learn
from experts: do you know about these
emerging industry trends?
CAR-T Cell Therapies:
Addressing Key Unmet Needs Across Various Oncological Indications
Learn from our recently published
whitepaper: -
Next
Generation Biomanufacturing – The Upcoming Era of Digital Transformation
About Roots Analysis
Roots Analysis is a global leader in the
pharma / biotech market research. Having worked with over 750 clients
worldwide, including Fortune 500 companies, start-ups, academia, venture
capitalists and strategic investors for more than a decade, we offer a highly
analytical / data-driven perspective to a network of over 450,000 senior
industry stakeholders looking for credible market insights.
Learn more about Roots
Analysis consulting services:
Roots Analysis Consulting - the
preferred research partner for global firms
Contact:
Ben Johnson
+1 (415) 800 3415
Roots Analysis has done
a detailed study on “Global Antibiotics Market 2023–2035””
report to its list of covering
key aspects of the industry’s evolution and identifying potential future growth
opportunities.
Key Market Insights
§
Presently,
around 60 players worldwide are engaged in the development of novel antibiotics
to treat a wide range of clinical conditions; majority of such players are
headquartered in North America.
§
Close
to 70% of the antibiotics have been approved for use in North America, specifically
the US; majority of these therapies are quinolones approved for the prevention
/ treatment of pulmonary infections.
§
Currently,
150 clinical-stage antibiotics are being evaluated across different stages of
preclinical / clinical development, either as monotherapies or in combination
with other drugs to target various types of bacteria.
§
Given
the rising prevalence of bacterial infections, over 50 stakeholders are focused
on the development and evaluation of antibiotics targeting a wide range of gram
positive and negative bacterial strains.
§
The
growing interest in this domain is evident from the rise in partnership
activity; in fact, the maximum number of collaborations related to antibiotics
have been inked in the last three years.
§
Since
2010, over 1,720 clinical trials have been registered to evaluate the safety
and efficacy of various antibiotics; majority of these studies have been
conducted across various sites in the US.
§
Several
researchers from renowned universities, currently involved in evaluating
efficacy and safety of antibiotics, have emerged as key opinion leaders (KOL);
of these, majority of the KOLs are Doctors of Medicine.
§
The global antibiotics marketis
anticipated to grow at a steady pace in coming decade; majority of the share is
captured by drugs targeting urinary tract infections.
§
The opportunity associated with the global antibiotic marketis
likely to be well distributed across various types of therapies, routes of
administration and key geographical regions.
§
Informed
estimates of the existing global antibiotics
market sizeand the
future opportunity, over the next decade. Based on multiple parameters, such as
drug class, mechanism of action, nature of source, target disease indication,
type of therapy, routes of administration and key geographical regions. We have
provided informed estimates on the evolution of the market for the period
2020-2030.
Table of Contents
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
1. EXECUTIVE
SUMMARY
2. INTRODUCTION
2.1. Overview of
Antibiotics
2.2. Characteristics
of an Ideal Antibiotic
2.3. Advantages of
Antibiotics
2.4. Classification
of Antibiotics
2.5. History of
Antibiotics
2.6. Developments
in Antibiotics during the Discovery Void
2.7. Mechanism of
Action of Antibiotics
2.8. Challenges
associated with the use of Antibiotics
2.9. Future
Perspectives
3. MARKET LANDSCAPE:
APPROVED ANTIBIOTIC GENERICS
3.1. Approved
Antibiotic Generics: Overall Market Landscape
3.2. Approved
Antibiotic Generics: Developer Landscape
4. MARKET
LANDSCAPE: APPROVED ANTIBIOTIC BRANDS
4.1. Approved
Antibiotic Brands: Overall Market Landscape
4.2. Approved
Antibiotic Brands: Developer Landscape
5. MARKET
LANDSCAPE: CLINICAL-STAGE ANTIBIOTICS
5.1. Clinical-stage
Antibiotics: Overall Market Landscape
5.2. Clinical-stage
Antibiotics: Developer Landscape
6. COMPANY
PROFILES
6.1. Bristol-Myers
Squibb
6.1.1. Company
Overview
6.1.2. Key Executives
6.1.3. Financial
Information
6.1.4. Product
Portfolio
6.1.5. Recent
Developments
6.1.6. Key Strategies
6.1.7. Key Focus Areas
6.1.8. Expert Opinion
6.3. GlaxoSmithKline
6.4. Melinta
Therapeutics
6.5. Merck
6.6. Pfizer
6.7. Concluding
Remarks
7. PARTNERSHIPS
AND COLLABORATIONS ANALYSIS
7.1. Partnership
Models
7.2. Antibiotics:
List of Partnerships and Collaborations
8. CLINICAL
TRIAL ANALYSIS
8.1. Analysis
Methodology and Key Parameters
8.2. Antibiotics:
Clinical Trial Analysis
9. KEY OPINION
LEADERS
9.1. Assumptions
and Key Parameters
9.2. Methodology
9.3. Antibiotics:
Key Opinion Leaders (KOLs)
10. KEY TRENDS IN
ANTIBIOTICS INDUSTRY
10.1. Impact of
COVID-19 on Antibiotics Industry
10.2. Key Trends in
Antibiotics Domain Post-COVID-19
10.3. Outsourcing
Trends
10.4 Drug Pricing
Analysis by Drug Class
11. APPROVED
ANTIBIOTICS: SUCCESS PROTOCOL ANALYSIS
11.1. Chapter
Overview
11.2. Methodology and
Scoring Criteria
11.3. Success
Protocol Analysis of Recently Approved Antibiotic Brands
11.4. Concluding
Remarks
12. MARKET
FORECAST AND OPPORTUNITY ANALYSIS
12.1. Chapter
Overview
12.2. Methodology and
Key Parameters
12.3. Global Market
opportunity, 2023-2035 (USD Billion)
13. APPENDIX I:
TABULATED DATA
14. APPENDIX II:
LIST OF COMPANIES AND ORGANIZATIONS
To
view more details on this report, click on the link:
https://www.rootsanalysis.com/reports/global-antibiotics-market.html
Learn
from experts: do you know about these
emerging industry trends?
Patient
Recruitment – Key Determinant of Successful Clinical Trials
Exploring AI-based
Digital Pathology
Learn from our recently published
whitepaper: -
Next
Generation Biomanufacturing – The Upcoming Era of Digital Transformation
About Roots Analysis
Roots Analysis is a global leader in the
pharma / biotech market research. Having worked with over 750 clients
worldwide, including Fortune 500 companies, start-ups, academia, venture
capitalists and strategic investors for more than a decade, we offer a highly
analytical / data-driven perspective to a network of over 450,000 senior
industry stakeholders looking for credible market insights.
Learn more about Roots
Analysis consulting services:
Roots Analysis Consulting - the
preferred research partner for global firms
Contact:
Ben Johnson
+1 (415) 800 3415